Research programme: RNA-targeted therapeutics - GlaxoSmithKline
Latest Information Update: 04 Dec 2014
At a glance
- Originator GlaxoSmithKline
- Class Antisense RNA; Oligonucleotides
- Mechanism of Action Antisense RNA inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Unspecified
Most Recent Events
- 10 Jan 2014 Early reseach in Undefined indication in United Kingdom (unspecified route)